Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV) (“Vodis” or the “Company”) announced today the Vodis name, image and various Vodis-inspired designs and concepts will be used to brand, market, and sell marijuana products across Washington State through a Product Licensing and Marketing Agreement (the “Licensing Agreement”) between a Washington State marijuana licensee, Our Church International, LLC (“OCI”), and Vodis’s wholly-owned subsidiary, Vodis USA, Inc. (“Vodis USA”).

The Licensing Agreement entered into by Vodis USA and its Bellingham facility tenant, OCI, will result in the Vodis name and related images being used for branding, marketing, and commercialization of OCI’s cannabis products. In addition, with Vodis developing marketing strategies and providing operational support we expect the Vodis brand will become synonymous across and eventually beyond the State of Washington with premium-branded cannabis products. “This is an important step to continue developing the association between the Vodis brand and high quality, consumer recognized cannabis products. We have worked hard with the OCI team to ensure all Vodis branding will be associated with the best OCI has to offer,” stated Vodis CEO Ivan Miliovski.


This agreement is seen by Vodis not only as a source of additional value-added revenue from its client OCI, but also as an important opportunity to capitalize on the recently announced Phase 2 production expansion at OCI’s Washington facility. Establishing early consumer recognition of Vodis USA as a premium cannabis brand through packaging and superior merchandising is key to immediate and long-term growth of sales and revenue for both companies.

Washington law prohibits non-residents from obtaining a percentage of profits from the operations of marijuana licensees. Accordingly, the Licensing Agreement between OCI and Vodis USA establishes a graduated compensation schedule increasing the compensation to Vodis USA as sales and marketing goals are achieved. The compensation schedule, based on gross aggregate sales, ranges from $0.34 to $0.40 per dollar of Vodis branded product sold by OCI. The company anticipates revenues to Vodis from Vodis branded cannabis products sold by OCI, at full operational capacity, would be in excess of $2.0M annually based on today’s market prices.

Cannabis sales in Washington exceeded $1.1B in FY 2016, offering a promising opportunity for both Vodis USA and OCI to capitalize on the ever-growing legal cannabis industry.


Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States. It can license its brand and production consulting services to approved Washington State license holders to ensure that all products produced under the Vodis name and/or associated with the “VIP” brand meet or exceed the Vodis brand quality standards.

Click here to read more about Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV)

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less